Fall Risk and Quality of Life: in Individuals With Cancer Treatment Related Peripheral Neuropathy.
Launched by TEXAS WOMAN'S UNIVERSITY · Mar 8, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how peripheral neuropathy, which is nerve damage caused by cancer treatment, affects the risk of falling and the quality of life for people who have had cancer. The researchers want to learn if issues with thinking, feeling, balancing, or moving around make someone more likely to fall or impact their daily life. They are also looking at how well participants can do two things at once, like walking while texting.
To participate in this study, individuals must be at least 18 years old and have been diagnosed with a type of cancer (excluding brain cancers) and show symptoms of peripheral neuropathy. There will also be a control group made up of similar-aged individuals who do not have peripheral neuropathy or any cognitive issues. Participants will be asked to complete some activities and share their experiences, helping the researchers understand the challenges faced by those with peripheral neuropathy. This study is currently recruiting and aims to provide valuable insights into improving the lives of cancer survivors dealing with nerve pain.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Experimental group
- • Individuals 18 years and older
- • diagnosed with non- CNS cancer who underwent treatment and presents with peripheral neuropathy symptoms.
- • Control group
- • age (+/- one year) and gender matched individuals
- • no diagnosed peripheral neuropathy
- • No diagnosed cognitive symptoms.
- Exclusion Criteria:
- • Unable to follow two step commands.
- • Unable to ambulate x 50 feet independently without use of an assistive device.
- • Unable to use a phone to send text messages.
- • Diagnosis of diabetic peripheral neuropathy
- • Diagnosis of CNS cancer.
- • Unable to speak/understand English
About Texas Woman's University
Texas Woman's University (TWU) is a leading institution dedicated to advancing health and wellness through innovative research and education. As a prominent clinical trial sponsor, TWU leverages its expertise in various fields, particularly in women's health, to design and conduct rigorous clinical studies that contribute to evidence-based practices and improved patient outcomes. Committed to ethical standards and community engagement, TWU collaborates with healthcare professionals and researchers to explore critical health issues, ultimately aiming to enhance the quality of life for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Patients applied
Trial Officials
Priya Karakkattil, PhD
Principal Investigator
Texas Woman's University
Asha Vas, PhD
Principal Investigator
Texas Woman's University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported